BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH AND Treatment
35 results:

  • 1. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
    Wang Y; Dackus GMHE; Rosenberg EH; Cornelissen S; de Boo LW; Broeks A; Brugman W; Chan TWS; van Diest PJ; Hauptmann M; Ter Hoeve ND; Isaeva OI; de Jong VMT; Jóźwiak K; Kluin RJC; Kok M; Koop E; Nederlof PM; Opdam M; Schouten PC; Siesling S; van Steenis C; Voogd AC; Vreuls W; Salgado RF; Linn SC; Schmidt MK
    BMC Med; 2024 Jan; 22(1):9. PubMed ID: 38191387
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Morphological Changes of the ovarian Vein in Pelvic Venous Disorders.
    Nykonenko A; Trailin A; Lazarashvili Z; Proczka RM; Havrylenko B; Nykonenko O
    Eur J Vasc Endovasc Surg; 2024 Mar; 67(3):500-505. PubMed ID: 37952635
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer.
    Nara K; Taguchi A; Yamamoto T; Hara K; Tojima Y; Honjoh H; Nishijima A; Eguchi S; Miyamoto Y; Sone K; Mori M; Takada T; Osuga Y
    Int J Clin Oncol; 2023 Sep; 28(9):1207-1217. PubMed ID: 37347381
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study.
    Yoshihara M; Mogi K; Kitami K; Uno K; Iyoshi S; Tano S; Fujimoto H; Miyamoto E; Yoshikawa N; Emoto R; Matsui S; Kajiyama H
    Int J Clin Oncol; 2022 Oct; 27(10):1660-1668. PubMed ID: 35906336
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Clinical Approach to Neuroendocrine Neoplasm Associated With ovarian Teratoma.
    Opalińska M; Sowa-Staszczak A; Olearska H; Ulatowska-Bialas M; Gilis-Januszewska A; Hubalewska-Dydejczyk A
    Front Endocrinol (Lausanne); 2021; 12():770266. PubMed ID: 34917031
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Clinical and pathological analysis of companion diagnostic testing of microsatellite instability-high for pembrolizumab in gynaecologic malignancy.
    Takeda T; Tsuji K; Kobayashi Y; Banno K; Aoki D
    Jpn J Clin Oncol; 2022 Feb; 52(2):128-133. PubMed ID: 34750611
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
    Thein KZ; Karp DD; Tsimberidou A; Gong J; Sulovic S; Shah J; Milton DR; Hong DS; Janku F; McQuinn L; Stephen BA; Colen R; Carter BW; Yap TA; Piha-Paul SA; Fu S; Meric-Bernstam F; Naing A
    Invest New Drugs; 2022 Apr; 40(2):290-299. PubMed ID: 34562230
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. First case report of papillary thyroid carcinoma arising within a functional teratoma in Graves' disease patient.
    Cheng CC; Ting-An ; Chang ; Yang WP
    Gynecol Endocrinol; 2021 Oct; 37(10):955-958. PubMed ID: 34180765
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
    Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Zarifa A; Shah J; Milton DR; Bean S; McQuinn L; Gong J; Colen R; Carter BW; Subbiah V; Ogbonna DC; Pant S; Meric-Bernstam F; Naing A
    Invest New Drugs; 2021 Oct; 39(5):1357-1365. PubMed ID: 33909232
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.
    Kato MK; Yunokawa M; Bun S; Shimoi T; Yonemori K; Miyasaka N; Kato T; Tamura K
    J Cancer Res Clin Oncol; 2020 May; 146(5):1335-1341. PubMed ID: 32144536
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma.
    Berg HF; Ju Z; Myrvold M; Fasmer KE; Halle MK; Hoivik EA; Westin SN; Trovik J; Haldorsen IS; Mills GB; Krakstad C; Werner HMJ
    Br J Cancer; 2020 Mar; 122(7):1014-1022. PubMed ID: 32037399
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. ovarian metastases reported after adjuvant laparoscopic oophorectomies in breast cancer.
    Cristian DA; Grama FA; Becheanu G; Popa I; Bratu AM; Burcoş T; Poalelungi CV; Şurlin V
    Rom J Morphol Embryol; 2019; 60(3):913-920. PubMed ID: 31912104
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. ovarian cancer metastasis to the breast 18 years after the initial diagnosis: A case report.
    Wang Z; Zhao D; Liu R; Zheng B
    Medicine (Baltimore); 2019 Oct; 98(43):e17577. PubMed ID: 31651861
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Reannotation and Analysis of Clinical and Chemotherapy Outcomes in the ovarian Data Set From The cancer Genome Atlas.
    Villalobos VM; Wang YC; Sikic BI
    JCO Clin Cancer Inform; 2018 Dec; 2():1-16. PubMed ID: 30652548
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Napsin-A, a Possible Diagnostic Marker for Differentiating Clear Cell ovarian Carcinoma From Other High-grade ovarian Carcinomas.
    Alshenawy HA; Radi DA
    Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):605-610. PubMed ID: 28362708
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Impact of XRCC1, GSTP1, and GSTM1 Polymorphisms on the Survival of ovarian Carcinoma Patients Treated with Chemotherapy.
    Zhai XH; Huang J; Wu FX; Zhu DY; Wang AC
    Oncol Res Treat; 2016; 39(7-8):440-6. PubMed ID: 27487108
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.
    Mirkin S; Pinkerton JV; Kagan R; Thompson JR; Pan K; Pickar JH; Komm BS; Archer DF
    J Womens Health (Larchmt); 2016 May; 25(5):431-42. PubMed ID: 27058301
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
    Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
    PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
    Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
    Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population.
    Li K; Li W
    Mol Cell Biochem; 2013 Jan; 372(1-2):27-33. PubMed ID: 22983827
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.